vorinostat 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
histone deacetylase inhibitors 4124 149647-78-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • vorinostat
  • suberoylanilide hydroxamic acid
A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
  • Molecular weight: 264.33
  • Formula: C14H20N2O3
  • CLOGP: 0.99
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 3
  • TPSA: 78.43
  • ALOGS: -3.57
  • ROTB: 8
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 43 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 28 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.29 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.76 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 6, 2006 FDA MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 154.40 39.51 65 1195 105480 56185327
Electrocardiogram QT prolonged 80.74 39.51 34 1226 54554 56236253
Dehydration 58.47 39.51 39 1221 158786 56132021
Cutaneous T-cell lymphoma 42.17 39.51 9 1251 1366 56289441
Sepsis 41.22 39.51 30 1230 139810 56150997
Platelet count decreased 41.19 39.51 27 1233 106356 56184451
Thrombocytopenia 39.64 39.51 29 1231 136195 56154612

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Torsade de pointes 79.09 31.17 24 1523 6826 31688971
Lymphopenia 58.20 31.17 23 1524 14306 31681491
Febrile neutropenia 46.47 31.17 42 1505 121807 31573990
Product use in unapproved indication 39.38 31.17 35 1512 99136 31596661
Anaemia 37.76 31.17 49 1498 213473 31482324
Electrocardiogram abnormal 36.50 31.17 14 1533 8022 31687775
Cutaneous T-cell lymphoma 34.95 31.17 9 1538 1402 31694395
Platelet count decreased 34.28 31.17 34 1513 110401 31585396
Activated partial thromboplastin time prolonged 32.66 31.17 13 1534 8212 31687585
Thrombocytopenia 32.04 31.17 37 1510 142710 31553087

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 128.58 31.44 85 2567 204233 70721559
Product use in unapproved indication 101.49 31.44 74 2578 207404 70718388
Torsade de pointes 77.03 31.44 28 2624 18088 70907704
Platelet count decreased 68.19 31.44 55 2597 178167 70747625
Cutaneous T-cell lymphoma 60.99 31.44 15 2637 2538 70923254
Acute myeloid leukaemia 59.34 31.44 27 2625 30913 70894879
Thrombocytopenia 50.64 31.44 53 2599 239057 70686735
Sepsis 44.41 31.44 50 2602 244495 70681297
Dehydration 42.36 31.44 47 2605 226095 70699697
Malignant neoplasm progression 41.12 31.44 35 2617 121704 70804088
Anaemia 35.55 31.44 58 2594 403365 70522427
Lymphopenia 34.70 31.44 18 2634 27341 70898451
Electrocardiogram abnormal 31.94 31.44 14 2638 14650 70911142

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01XH01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Histone deacetylase (HDAC) inhibitors
FDA MoA N0000175071 Histone Deacetylase Inhibitors
FDA EPC N0000175588 Histone Deacetylase Inhibitor
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D056572 Histone Deacetylase Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:61115 histone deacetylase inhibitors
CHEBI has role CHEBI:68495 Type I cell-death inducers

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Primary cutaneous T-cell lymphoma indication 400122007
Hypocalcemia contraindication 5291005
Dehydration contraindication 34095006
Hypokalemia contraindication 43339004
Diarrhea contraindication 62315008
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Prolonged QT interval contraindication 111975006
Deep venous thrombosis contraindication 128053003
Hypomagnesemia contraindication 190855004
Pulmonary thromboembolism contraindication 233935004
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Thromboembolic disorder contraindication 371039008
Breastfeeding (mother) contraindication 413712001
Vomiting contraindication 422400008
Congenital long QT syndrome contraindication 442917000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.34 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
100MG ZOLINZA MSD SUB MERCK N021991 Oct. 6, 2006 RX CAPSULE ORAL 7732490 March 4, 2023 TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)
100MG ZOLINZA MSD SUB MERCK N021991 Oct. 6, 2006 RX CAPSULE ORAL 8067472 March 4, 2023 TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)
100MG ZOLINZA MSD SUB MERCK N021991 Oct. 6, 2006 RX CAPSULE ORAL 8101663 March 4, 2023 TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)
100MG ZOLINZA MSD SUB MERCK N021991 Oct. 6, 2006 RX CAPSULE ORAL 7851509 Feb. 21, 2024 TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)
100MG ZOLINZA MSD SUB MERCK N021991 Oct. 6, 2006 RX CAPSULE ORAL 7399787 Feb. 9, 2025 TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)
100MG ZOLINZA MSD SUB MERCK N021991 Oct. 6, 2006 RX CAPSULE ORAL 8450372 March 18, 2028 TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Histone deacetylase 2 Enzyme INHIBITOR Ki 8.80 CHEMBL CHEMBL
Histone deacetylase 1 Enzyme INHIBITOR Ki 8.89 CHEMBL CHEMBL
Histone deacetylase 3 Enzyme INHIBITOR Ki 8.30 CHEMBL CHEMBL
Histone deacetylase 6 Enzyme INHIBITOR Ki 9 CHEMBL CHEMBL
Histone deacetylase 8 Enzyme Ki 6.76 CHEMBL
Histone deacetylase 4 Enzyme Ki 7.80 CHEMBL
Histone deacetylase 9 Enzyme Ki 7.31 CHEMBL
Leukotriene A-4 hydrolase Enzyme IC50 5.12 CHEMBL
Histone deacetylase 10 Enzyme Ki 7.30 CHEMBL
Histone deacetylase 11 Enzyme Ki 7.89 CHEMBL
Lysine-specific demethylase 4E Enzyme IC50 4.85 CHEMBL
Bromodomain-containing protein 4 Unclassified IC50 8 CHEMBL
Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2) Transcription factor Ki 8.70 CHEMBL
Histone deacetylase 3/NCoR1 Transcription factor Ki 7.92 CHEMBL
Histone deacetylase Enzyme IC50 8 CHEMBL
Histone deacetylase 1/3/5/8 Enzyme IC50 6.96 CHEMBL
Histone deacetylase (HDAC1 and HDAC2) Enzyme IC50 8 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.49 CHEMBL
Epidermal growth factor receptor Kinase IC50 6.05 CHEMBL
Histone deacetylase 5 Enzyme Ki 7.48 CHEMBL
Histone deacetylase 7 Enzyme Ki 6.89 CHEMBL
HD2 type histone deacetylase HDA106; Histone deacetylase 2b; Uncharacterized protein Enzyme IC50 7.30 CHEMBL
Histone deacetylase 1 Enzyme IC50 6.95 CHEMBL
Histone deacetylase Enzyme IC50 7.55 CHEMBL
Histone deacetylase Enzyme IC50 7.23 CHEMBL
Histone deacetylase-like amidohydrolase Enzyme Kd 6.52 CHEMBL
Histone deacetylase Enzyme IC50 7 CHEMBL
Histone deacetylase Enzyme IC50 6.78 CHEMBL
Histone deacetylase 8 Unclassified IC50 6.23 CHEMBL
Leukotriene A-4 hydrolase Enzyme IC50 5.21 CHEMBL
Protein Tat Unclassified EC50 5.64 CHEMBL

External reference:

IDSource
4025777 VUID
N0000179580 NUI
D06320 KEGG_DRUG
4025777 VANDF
C0672708 UMLSCUI
CHEBI:45716 CHEBI
CHEMBL98 ChEMBL_ID
D000077337 MESH_DESCRIPTOR_UI
DB02546 DRUGBANK_ID
6852 IUPHAR_LIGAND_ID
8661 INN_ID
58IFB293JI UNII
5311 PUBCHEM_CID
194337 RXNORM
22259 MMSL
d05891 MMSL
011760 NDDF
422505001 SNOMEDCT_US
422523009 SNOMEDCT_US
SHH PDB_CHEM_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ZOLINZA HUMAN PRESCRIPTION DRUG LABEL 1 0006-0568 CAPSULE 100 mg ORAL NDA 30 sections
ZOLINZA HUMAN PRESCRIPTION DRUG LABEL 1 0006-0568 CAPSULE 100 mg ORAL NDA 30 sections